The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: A validation study
Background. The purpose of this study was to assess the reproducibility of the previously describedT2–fluid attenuated inversion recovery (FLAIR) mismatch sign as a specific imaging marker in non-enhancing isocitrate dehydrogenase (IDH) mutant, 1p/19q non-codeleted lower-grade glioma (LGG), encompassing both diffuse and anaplastic astrocytoma. Methods. MR scans (n = 154) from 3 separate databases with genotyped LGG were evaluated by 2 independent reviewers to assess (i) presence/absence of “T2-FLAIR mismatch” sign and (ii) presence/absence of homogeneous signal onT2-weighted images. Interrater agreement with Cohen's kappa (κ) was calculated, as well as diagnostic test performance of theT2-FLAIR mismatch sign to identify IDH-mutant astrocytoma. Results. There was substantial interrater agreement for theT2-FLAIR mismatch sign [κ = 0.75 (0.64–0.87)], but only fair agreement forT2 homogeneity [κ = 0.38 (0.25–0.52)].TheT2-FLAIR mismatch sign was present in 38 cases (25%) and had a positive predictive value of 100%, negative predictive value of 68%, a sensitivity of 51%, and a specificity of 100%. Conclusions. With a robust interrater agreement, our study confirms that among non-enhancing LGG theT2-FLAIR mismatch sign represents a highly specific imaging marker for IDH-mutant astrocytoma.This non-invasive marker may enable a more informed patient counsel and can aid in the treatment decision processes in a significant proportion of patients presenting with non-enhancing, LGG-like lesions.
|Keywords||IDH-mutant astrocytoma, Imaging marker, Lower grade glioma |T2-FLAIR|
|Persistent URL||dx.doi.org/10.1093/neuonc/noy048, hdl.handle.net/1765/114299|
Broen, M.P.G, Smits, M, Wijnenga, M.M.J, Dubbink, H.J, Anten, M.H.M.E, Schijns, O.E.M.G, … van den Bent, M.J. (2018). The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: A validation study. Neuro-Oncology, 20(10), 1393–1399. doi:10.1093/neuonc/noy048